
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has demonstrated substantial growth in its operations, with Q4 revenue reaching $239.7 million, representing a 24.5% year-over-year increase, and earnings per share of $1.15 surpassing consensus estimates. The company has also seen a steady rise in the utilization of its Inspire therapy, which increased from 1.1 procedures per month in 2021 to 1.8 in 2024, indicating growing demand and effectiveness of its solutions for obstructive sleep apnea. The anticipated expansion of implanting centers, along with innovations such as the upcoming Gen 5 device and new treatment options, positions Inspire Medical Systems for continued revenue growth and market penetration.
Bears say
Inspire Medical Systems faces a negative outlook primarily due to potential challenges in market penetration and utilization of its implant centers, which could delay its path to profitability and allow new entrants to capture market share. Revenue estimates for 2025 remain stagnant and modestly below management guidance, indicating a lack of growth momentum, while expectations for earnings per share have also been revised downwards, suggesting some caution regarding future performance. Additionally, there are concerns that advertising expenditure, although decreasing as a percentage of revenue, may not generate sufficient returns to support increased sales in a competitive landscape.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares